Increasing Uptake of Cascade Testing in Families With Familial Cancer Syndromes: A Randomized Con… (NCT07626814) | Clinical Trial Compass
CompletedNot Applicable
Increasing Uptake of Cascade Testing in Families With Familial Cancer Syndromes: A Randomized Controlled Trial of a Registry-aided Model.
Singapore545 participantsStarted 2021-12-10
Plain-language summary
The purpose of this study is to compare the uptake rates of a patient-initiated model of cascade testing with a registry-aided model amongst relatives of patients identified to have a particular cancer predisposition gene. Cascade testing allows the benefits of genetic testing to spread beyond the patient and enables other family members to make an informed choice on genetic testing. The researcher team hopes to study the rates of cascade testing using the two models, while concurrently comparing the adherence of identified carriers to risk management recommendations, including surveillance imaging and/or prophylactic surgeries. The team also aims to understand the willingness, acceptability and barriers of a registry-aided model.
Who can participate
Age range
21 Years – 99 Years
Sex
ALL
See this in plain English?
AI-rewrites the medical criteria so a patient or caregiver can understand them. Always confirm with the trial site.
Inclusion Criteria:
Probands:
* Patients who undergo clinical genetic testing and seen at the Cancer Genetics Service (CGS) in National Cancer Centre Singapore
* Pathogenic variant/ likely pathogenic variant (PV/LPV) identified in a cancer predisposition gene
* Aged 21 years old and over
* Singapore citizen or permanent resident
ARRs:
* ARRs of a proband
* Aged 21 years old and over
* Singapore citizen or permanent resident
Exclusion Criteria:
* Lacks capacity to consent
* Not living in Singapore
* Probands who decline to share relatives' contact details
* Probands with no contactable relatives in Singapore
Questions worth asking your doctor
Bring these to your next appointment. They're a starting point for a shared conversation — not a sign you qualify or a recommendation to enrol.
1Based on my diagnosis and history, is this trial worth exploring for me — or is there a standard treatment we should try first?
2What does this trial's phase tell us about how much is already known about its safety and benefit?
3What would taking part actually involve for me — visits, tests, time, and travel?
4What are the known and possible risks or side effects I should weigh, and how would they be monitored?
5If this trial isn't the right fit, what other options or trials would you suggest I look into?
Generated to help you prepare — always confirm anything about your own eligibility and care with the study team and your doctor.
Questions for the trial coordinator
The trial coordinator is the person who runs the study day to day. These cover the practical side — logistics, costs, and what taking part would actually mean for your life. The study team confirms whether you meet the criteria; these are questions to ask, not a sign you qualify.
1What does taking part actually involve week to week — how many visits, where, and how long does each one take?
2What costs are covered by the study, and what might I have to pay for myself, including travel, parking, or time off work?
3What happens during screening, and what happens if the study team confirms I don't meet the criteria after those tests?
4Who pays for the scans, blood work, and other tests the trial requires — the study, my insurance, or me?
5How will being in the trial affect my regular care, and will my own doctor stay informed and involved?
6Can I leave the trial at any point if I change my mind, and what would happen to my care if I do?
A starting point for the conversation — always confirm anything about your own eligibility, costs, and care with the study team and your doctor.
What they're measuring
1
Uptake of cascade genetic testing.
Timeframe: Up to 6 months after proband randomisation.